TR200102557T2 - Thiazonlindolinone compounds. - Google Patents

Thiazonlindolinone compounds.

Info

Publication number
TR200102557T2
TR200102557T2 TR2001/02557T TR200102557T TR200102557T2 TR 200102557 T2 TR200102557 T2 TR 200102557T2 TR 2001/02557 T TR2001/02557 T TR 2001/02557T TR 200102557 T TR200102557 T TR 200102557T TR 200102557 T2 TR200102557 T2 TR 200102557T2
Authority
TR
Turkey
Prior art keywords
thiazonlindolinone
compounds
thiazole
severity
inhibitors
Prior art date
Application number
TR2001/02557T
Other languages
Turkish (tr)
Inventor
Vyas Ambrish
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200102557T2 publication Critical patent/TR200102557T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Abstract

Kemoterapi ve/veya radyasyon tedavisi gören bir hastada, bu tip bir tedavinin epitel sitotoksikliği yan etkilerinin ciddiliğinin önlenmesi/azaltılması için, sikline bağlı kinaz II inhibitörleri olarak yararlı olan tiazol-indol bileşikleri tarif edilmektedir.In a patient undergoing chemotherapy and / or radiation therapy, thiazole-indole compounds useful as cyclin dependent kinase II inhibitors are described to prevent / reduce the severity of epithelial cytotoxicity side effects of such treatment.

TR2001/02557T 1999-03-04 2000-03-01 Thiazonlindolinone compounds. TR200102557T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9904930.6A GB9904930D0 (en) 1999-03-04 1999-03-04 Thiazoloindolinone compounds

Publications (1)

Publication Number Publication Date
TR200102557T2 true TR200102557T2 (en) 2007-01-22

Family

ID=10848912

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02557T TR200102557T2 (en) 1999-03-04 2000-03-01 Thiazonlindolinone compounds.

Country Status (18)

Country Link
EP (1) EP1159280A2 (en)
JP (1) JP2003532620A (en)
KR (1) KR20020005606A (en)
CN (1) CN1355807A (en)
AU (1) AU3611000A (en)
BR (1) BR0008677A (en)
CA (1) CA2361580A1 (en)
CZ (1) CZ20013187A3 (en)
GB (1) GB9904930D0 (en)
HK (1) HK1041692A1 (en)
HU (1) HUP0200376A3 (en)
IL (1) IL144808A0 (en)
MX (1) MXPA01008910A (en)
NO (1) NO20014262L (en)
PL (1) PL351476A1 (en)
TR (1) TR200102557T2 (en)
WO (1) WO2000052013A2 (en)
ZA (1) ZA200106826B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO2006060615A1 (en) * 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Non-hygroscopic and powdery amorphous pimecrolimus
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP4761000B1 (en) * 2010-11-08 2011-08-31 小野薬品工業株式会社 Preventive and / or therapeutic agent for hand-foot syndrome
ES2604705T3 (en) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Preventive agent and / or remedy for hand-foot syndrome
WO2019114705A1 (en) 2017-12-13 2019-06-20 上海小午医药科技有限公司 Method for preventing or treating disease related to egfr inhibition
AU2019254237A1 (en) 2018-04-16 2020-12-03 Onquality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0984930B1 (en) * 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives

Also Published As

Publication number Publication date
HUP0200376A2 (en) 2002-06-29
HUP0200376A3 (en) 2003-07-28
IL144808A0 (en) 2002-06-30
EP1159280A2 (en) 2001-12-05
CZ20013187A3 (en) 2002-02-13
CA2361580A1 (en) 2000-09-08
PL351476A1 (en) 2003-04-22
MXPA01008910A (en) 2002-03-27
NO20014262L (en) 2001-10-30
CN1355807A (en) 2002-06-26
AU3611000A (en) 2000-09-21
JP2003532620A (en) 2003-11-05
KR20020005606A (en) 2002-01-17
WO2000052013A3 (en) 2000-12-28
WO2000052013A2 (en) 2000-09-08
BR0008677A (en) 2002-01-08
HK1041692A1 (en) 2002-07-19
GB9904930D0 (en) 1999-04-28
ZA200106826B (en) 2003-02-25
NO20014262D0 (en) 2001-09-03

Similar Documents

Publication Publication Date Title
NO20032759D0 (en) 2-phenylbenzimidazoles and imidazo [4,5] pyridines as SDSI / CHK2 inhibitors and adjuvants in chemotherapy or radiation therapy in the treatment of cancer
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
TR200102020T2 (en) W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors.
EA200101166A1 (en) Metalloprotease inhibitors
IL191832A (en) Pyridiazinone compounds and their use in the preparation of medicaments for treating tumours
TW200638945A (en) Combination therapy
BRPI0413427A (en) active pyridylpyrrole derivatives as kinase inhibitors
GEP20033092B (en) Purine Inhibitors of Cyclin Dependent Kinase 2 and Ik-Aa
TR200200160T2 (en) Imidazoles and triazoles as anti-inflammatory agents
RS48804A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
RS20050945A (en) Novel pyrrolodihydroisoquinolines useful in the treatment of cancer
ATE363896T1 (en) DOSAGE FORM PROVEN AGAINST ABUSE
UA84954C2 (en) Fused pyrimidones usefuel in the treatment and the prevention of cancer
NO20050640L (en) Ruthenium anticancer complexes
EA200801430A1 (en) TRIAZOLE DERIVATIVES
NO20051040L (en) Use of alkylphosphocholines in combination with antitumor drugs
NO20024076D0 (en) Composition comprising camptotecin and a pyrimidine derivative for the treatment of cancer
TR200103271T2 (en) Anti-inflammatory therapy for infection that occurs through inflammation.
TR200102557T2 (en) Thiazonlindolinone compounds.
TR200002203T2 (en) Treatment of follicular lymphomas using inhibitors of the lysophoxin (LT) expression pathway.
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
DK1244643T3 (en) tryptase
NO20055650D0 (en) Ruteinum (II) complexes for the treatment of tumors
ATE268322T1 (en) INHIBITORS OF TRYPTASE